The Impact of Selecting a High Hemoglobin Target Level on Health-Related Quality of Life for Patients With Chronic Kidney Disease | Zendy

Fiona Clement | Zendy; Scott Klarenbach | Zendy; Marcello Tonelli | Zendy; Jeffrey Johnson | Zendy; Braden Manns | Zendy

Open Access

The Impact of Selecting a High Hemoglobin Target Level on Health-Related Quality of Life for Patients With Chronic Kidney Disease

Author(s) -

Fiona Clement,

Scott Klarenbach,

Marcello Tonelli,

Jeffrey Johnson,

Braden Manns

Publication year - 2009

Publication title -

archives of internal medicine

Language(s) - English

Resource type - Journals

eISSN - 1538-3679

pISSN - 0003-9926

DOI - 10.1001/archinternmed.2009.112

Subject(s) - medicine , quality of life (healthcare) , kidney disease , confidence interval , anemia , epoetin alfa , randomized controlled trial , hemoglobin , physical therapy , darbepoetin alfa , renal function , nursing

Treatment of anemia in chronic kidney disease (CKD) with erythropoietin-stimulating agents (ESAs) is commonplace. The optimal hemoglobin treatment target has not been established. A clearer understanding of the health-related quality of life (HQOL) impact of hemoglobin target levels is needed. We systematically reviewed the randomized controlled trial (RCT) data on HQOL for patients treated with low to intermediate (9.0-12.0 g/dL) and high hemoglobin target levels (>12.0 g/dL) and performed a meta-analysis of all available 36-item short-form (SF-36) RCT data.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research